Genezen vs ReciBioPharm: CDMO Comparison
How does Genezen compare to ReciBioPharm for AAV manufacturing?
Side-by-side comparison of Genezen and ReciBioPharm on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Genezen has FDA inspections on record (1); ReciBioPharm does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- ReciBioPharm maintains 3 MHRA / UK GMP certificates; Genezen does not.
On a 13-modality CDMO landscape, both Genezen and ReciBioPharm qualify as AAV manufacturers; ReciBioPharm carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both Genezen and ReciBioPharm qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: Genezen vs ReciBioPharm
How does Genezen compare to ReciBioPharm for AAV manufacturing?
On CDMO Signal's composite Signal Score, Genezen is 78/100 and ReciBioPharm is 83/100; Genezen has 1 FDA inspection on record vs 0 for ReciBioPharm; European coverage is 0 active EMA+MHRA certificates for Genezen vs 3 for ReciBioPharm. Both are tracked in the CDMO Signal directory as AAV CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Genezen or ReciBioPharm?
Both Genezen and ReciBioPharm maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Genezen has 1 FDA inspection on record; ReciBioPharm has 0.
How do Genezen and ReciBioPharm compare on European GMP coverage?
Genezen holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. ReciBioPharm holds 0 active EMA GMP certificates and 3 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for AAV manufacturing — Genezen or ReciBioPharm?
Both Genezen and ReciBioPharm are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Genezen carries a Signal Score of 78/100 and ReciBioPharm carries 83/100 — essentially tied for ReciBioPharm. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →